Intersect ENT (XENT) Tops Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. CDNS
2. AVGO
3. SPY
4. META
5. JBLU
6. ANT
7. SSD
8. ARTV
9. AAPL
10. INTC

Go back to Intersect ENT (XENT) Tops Q3 EPS by 4c

Intersect ENT Reports Third Quarter 2017 Results

November 2, 2017 4:05 PM EDT

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2017. Third quarter 2017 revenue was $22.3 million, a 21% increase over the third quarter 2016.

Recent Business Highlights

In October 2017, the company announced the presentation of the results of RESOLVE II, a pivotal phase III study evaluating the safety and efficacy of SINUVA, an investigational steroid releasing sinus implant, at... More